tradingkey.logo

Maravai LifeSciences Holdings Inc

MRVI
查看詳細走勢圖
3.270USD
-0.030-0.91%
收盤 12/26, 16:00美東報價延遲15分鐘
473.23M總市值
虧損本益比TTM

Maravai LifeSciences Holdings Inc

3.270
-0.030-0.91%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

-0.91%

5天

-4.66%

1月

-10.16%

6月

+32.39%

今年開始到現在

-40.00%

1年

-40.55%

查看詳細走勢圖

操作建議

Maravai LifeSciences Holdings Inc當前公司基本面數據相對健康,增長潛力較大。當前估值合理,在生物技術與醫療研究行業排名115/404位。機構持股佔比非常高,近一個月多位分析師給出公司評級為買入。最高目標價3.86。中期看,股價處於平穩狀態。近一個月,市場表現較差,但基本面評分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Maravai LifeSciences Holdings Inc評分

相關信息

行業排名
115 / 404
全市場排名
232 / 4563
所屬行業
生物技術與醫療研究

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

分析師目標

基於 11 分析師
買入
評級
3.857
目標均價
+6.85%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Maravai LifeSciences Holdings Inc亮點

亮點風險
Maravai LifeSciences Holdings, Inc. is a life sciences company providing critical products to enable the development of drug therapies, diagnostics and novel vaccines and to support research on human diseases. Its segments include Nucleic Acid Production Segment and Biologics Safety Testing Segment. The Nucleic Acid Production segment is focused on the manufacturing and sale of highly modified nucleic acids products to support the needs of customers’ research, therapeutic and vaccine programs. This segment’s business units include TriLink Discovery, TriLink GMP, Glen Research and Alphazyme. The Biologics Safety Testing segment is focused on manufacturing and selling biologics safety and impurity tests and assay development services that are utilized by its customers in their biologic drug manufacturing activities. This segment’s business is comprised of Cygnus Technologies. It serves various companies, including biopharmaceutical, vaccine, diagnostics and cell and gene therapy.
估值合理
公司最新PE估值-3.90,處於3年歷史合理位
機構減倉
最新機構持股128.65M股,環比減少25.67%
PRFDX持倉
明星投資者PRFDX持倉,最新持倉43.80K股

Maravai LifeSciences Holdings Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Maravai LifeSciences Holdings Inc簡介

Maravai LifeSciences Holdings, Inc. is a life sciences company providing critical products to enable the development of drug therapies, diagnostics and novel vaccines and to support research on human diseases. Its segments include Nucleic Acid Production Segment and Biologics Safety Testing Segment. The Nucleic Acid Production segment is focused on the manufacturing and sale of highly modified nucleic acids products to support the needs of customers’ research, therapeutic and vaccine programs. This segment’s business units include TriLink Discovery, TriLink GMP, Glen Research and Alphazyme. The Biologics Safety Testing segment is focused on manufacturing and selling biologics safety and impurity tests and assay development services that are utilized by its customers in their biologic drug manufacturing activities. This segment’s business is comprised of Cygnus Technologies. It serves various companies, including biopharmaceutical, vaccine, diagnostics and cell and gene therapy.
公司代碼MRVI
公司Maravai LifeSciences Holdings Inc
CEOBrust (Bernd)
網址https://www.maravai.com/

常見問題

Maravai LifeSciences Holdings Inc(MRVI)的當前股價是多少?

Maravai LifeSciences Holdings Inc(MRVI)的當前股價是 3.270。

Maravai LifeSciences Holdings Inc 的股票代碼是什麼?

Maravai LifeSciences Holdings Inc的股票代碼是MRVI。

Maravai LifeSciences Holdings Inc股票的52週最高點是多少?

Maravai LifeSciences Holdings Inc股票的52週最高點是6.210。

Maravai LifeSciences Holdings Inc股票的52週最低點是多少?

Maravai LifeSciences Holdings Inc股票的52週最低點是1.665。

Maravai LifeSciences Holdings Inc的市值是多少?

Maravai LifeSciences Holdings Inc的市值是473.23M。

Maravai LifeSciences Holdings Inc的淨利潤是多少?

Maravai LifeSciences Holdings Inc的淨利潤為-144.85M。

現在Maravai LifeSciences Holdings Inc(MRVI)的股票是買入、持有還是賣出?

根據分析師評級,Maravai LifeSciences Holdings Inc(MRVI)的總體評級為買入,目標價格為3.857。

Maravai LifeSciences Holdings Inc(MRVI)股票的每股收益(EPS TTM)是多少

Maravai LifeSciences Holdings Inc(MRVI)股票的每股收益(EPS TTM)是-0.839。
KeyAI